Show notes at pharmacyjoe.com/episode677. In this episode, I’ll discuss the efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease.

677: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease?

The Elective Rotation - the number 1 ranked Hospital Pharmacy podcast - is created for YOU Pharmacy Nation!  If you are a Pharmacy Student, Resident, Pharmacist, Nurse, Physician, or Critical Care Practitioner in a hospital, intensive care unit (ICU) or emergency department looking to improve your practice, The Elective Rotation delivers unbiased critical care and hospital pharmacy content from a Board Certified Pharmacotherapy Specialist. Episodes are published every Monday and Thursday at 3AM EST. Find the show notes at pharmacyjoe.com.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Show notes at pharmacyjoe.com/episode915. In this episode, I’ll discuss the rare case when a very hypotonic solution may be indicated.

915: The rare case when a very hypotonic solution may be indicated

Show notes at pharmacyjoe.com/episode914. In this episode, I’ll discuss oral vs IV phosphate replacement for critically ill patients with mild to moderate hypophosphatemia.

914: Does Oral Phosphate Replacement Work as Well as IV For Critically Ill Patients With Mild to Moderate Hypophosphatemia?

Show notes at pharmacyjoe.com/episode913. In this episode, I’ll discuss the efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease.

913: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease?

Show notes at pharmacyjoe.com/episode912. In this episode, I’ll discuss whether standard doses of apixaban are as effective as warfarin in severe obesity.

912: Are Standard Doses of Apixaban as Effective as Warfarin in Patients With Severe Obesity?

Show notes at pharmacyjoe.com/episode911. In this episode, I’ll discuss the risk of bacteremia in patients with asymptomatic bacteriuria and altered mental status.

677: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease?

Download our free app to listen on your phone